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Bacterial pneumonia is an important cause of
death. In Switzerland death related to a lung dis-
ease (including flu, pneumonia, chronic bronchi-
tis, and asthma) is very common: in 1997 the death
rate was 87.9/100,000 inhabitants [1]. Pneumonia
caused 27.6 deaths/100,000 inhabitants in 1997
which is comparable to the death rate caused by
colon cancer (25.8/100,000). In the US pneumo-
nia is the leading cause of death regarding infec-
tious diseases, and the sixth-leading cause of death
overall [2]. A general practitioner or internist
makes the diagnosis of pneumonia about ten times
a year [3]. It is important to make a quick diagno-
sis and refer the patient to the adequate treatment
in order to minimize complication rates; taking
blood cultures within 24 hours and administering
antibiotics within 8 hours of hospital admission has
been shown to be associated with improved sur-
vival [4]. To reach this goal, it is helpful to know
which diagnostic procedures are successful, what
empiric treatment to install, and which aetiologic
agents to suspect.
Community acquired pneumonia (CAP) re-
mains an important cause of substantial morbidity
and mortality in inhospital patients. 
We conducted a retrospective study of all pa-
tients hospitalised at our hospital with the diagno-
sis of bacterial pneumonia according to ICD-10
within one year. Of 360 identified charts, 335 met
the requirements and were reviewed regarding risk
factors, diagnosis, treatment, and overall mortality. 
The typical patient hospitalised with pneumo-
nia was elderly (mean 68 years), male (60%), and
suffered from comorbidities or predisposing factors
(96.4%). A total of 72.8% of pneumonias were lo-
calized in the inferior lobes, and 21.1% had bilat-
eral infiltrates. Etiologic agents were searched for in
297/335 patients (87.5%) and were found positive
in 33.4%: of 169 blood cultures 9.5% were positive,
of 150 sputum cultures taken 46.6% were positive,
of 17 serologies taken 58.8% were positive, and of
9 pleural effusions analysed 22.2% were positive.
Encapsulated bacteria were the most common
found bacterial etiologies, namely Streptococcus pneu-
moniae (S. pneumoniae) in 30.9% of patients with
known bacterial etiology, Haemophilus in 24.7%,
and Klebsiella in 12.4%. Methicillin-resistant S. au-
reus was not found. The three most commonly used
antibiotics were amoxicillin/clavulanic acid used 
in 77.3% of patients, clarithromycin (41.2%), and
ceftriaxone (16.6%). Mean duration of treatment
was 12.1 days. 245/335 (73.1%) patients had a
favourable outcome, 16.7% (56/335) of patients had
a protracted illness with delayed resolution (i.e. pro-
longed hospital stay, need for intensive care, intu-
bation or several of these complications).
Overall mortality in our unit was 8.6%.
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Summary
Introduction
Methods
We conducted a retrospective chart review at our re-
ferring hospital (727 active beds and 24,029 hospitalisa-
tions in 1998) of all patients 18 years of age or older who
were hospitalised between January 1st and December 31st
1998 with bacterial pneumonia according to ICD-10. The
ICD-codes included were A 02.2, 20.2, 22.1, 39.8, 48.0-1,
49.8; B 05.2; J 10.0, 11.0, 13, 14, 15.0-2, 15.4, 15.6, 15.9,
16.0, 17.0, 17.8, 18.0-2, 18.8-9, 69.0, 84.8, 85.1. Diagno-
sis was established at hospitalisation as well as confirmed
and coded by the treating doctors.
Data was collected from patient charts without stan-
dardisation questionnaire and included age, sex, and dif-
ferent comorbidities predisposing to bacterial pneumonia.
Furthermore, we extracted data regarding diagnostics,
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their success rate, the aetiologic agents identified during
hospitalisation, the kind of antibiotic treatment applied,
treatment duration, and finally overall mortality.
Pathogens were identified using conventional bacte-
riological techniques (gram stain, culture morphology,
biochemistry, and antigen testing) for sputum, blood cul-
tures, and pleural fluid as well as immunological assays for
detection of specific antibodies in serum. Sputum, pleu-
ral fluid, and positive blood cultures were cultivated on
different agar media. Pneumocci were cultivated on Co-
lumbia blood agar plates at 5% CO2, identification was
based on gram stain, culture morphology, optochin sus-
ceptibility, and bile solubility. Other streptococci were
cultured on blood agar and CNA blood agar plates. The
strains were then identified by gram stain, culture mor-
phology, and biochemical testing (ATB 32 Strep; Bio
Mérieux, France). Haemophilus influenzae was grown on
chocolate agar plates, and, together with S. aureus on
blood agar to observe a satelliting phenomenon. Identifi-
cation included gram stain and evaluation of growth in the
presence of V, X, and V+X factor. Moraxella catarrhalis was
cultured on blood agar plates with subsequent identifica-
tion by gram stain, oxidase and catalase, and biochemical
testing using OF media. Staphylococcus aureus was grown
on blood agar and CNA agar plates. Identification in-
cluded gram stain, catalase, clumping factor and free co-
agulase testing, and biochemical evaluation. Gram nega-
tive rods were grown on Mac Conkey agar plates, and fur-
ther identifiaction was based on fermenting properties.
Enterobacteriaceae such as Klebsiella sp., Enterobacter sp.,
Citrobacter sp., Proteus sp., and Morganella sp. were iden-
tified by commercially available biochemical test systems
(API 20 E, Bio Mérieux, France). Nonfermenting rods
like Pseudomonas aeruginosa and Acinetobacter sp. were
identified by growth on Cetrimide agar and growth at
42°C (P. aeruginosa), and gram stain and biochemical
testing for Acinetobacter sp. (API 20 NE, Bio Mérieux,
France). 
Serological testing for Chlamydia pneumoniae and My-
coplasma pneumoniae was accomplished by complement fix-
ation method (Virion, Switzerland), whereas Legionella an-
tibody titers were assessed by indirect immmunofluores-
cence technique (SCIMEDX, USA). 
Legionella serology was considered positive with a sin-
gle titer of 1:256 or more according to Stout [5], Chlamy-
dia pneumoniae serology was considered positive if IgM
alone or IgG and IgM were both positive.
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n %
Chronic obstructive pulmonary disease 81 24.2
Carcinoma ever 70 20.9
Smoking* 59 17.6
Coronary heart disease 37 11
Diabetes mellitus 37 11
Cardiopathies (non coronary heart disease) 25 7.5
Aspiration*, difficulty swallowing 23 6.9
Cerebrovascular insult 18 5.4
Alcoholism 17 5.1
Chronic renal insufficiency, Hemodialysis 13 3.9
Dementia 10 3
Chronic heart failure 8 2.4
M. Parkinson 5 1.5
Immunosuppression
HIV pos. (men only) 4 1.2
Renal transplant 2 0.6
Chronic lymphatic leukemia 2 0.6
Heart transplant 1 0.3
* smoking and aspiration are considered as predisposing factors not comorbidities 
Table 1
Comorbidities and
predisposing factors
to pneumonia 
(n = 335).
Etiologic agents assigned 33.4% (98/293) 
Blood cultures taken 57.7% (169/293) 
Positive blood cultures 9.5% (16/169 )
Sputum cultures taken 51.2% (150/293)
Positive sputum cultures 46.6% (70/150)
Serologic testing taken 6% (17/293)
Positive serology 58.8% (10/17)
Pleural effusion analyse 3% (9/293)
Positive pleural effusion 22.2% (2/9)
Table 2
Diagnostic features
(n = 293). Legionella
serology was consi-
dered positive with 
a single titer of 1:256
or more according 
to Stout [5].
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Results
Of 360 identified charts, 25 had to be excluded
because diagnosis of pneumonia could not be con-
firmed according to the documented data, or be-
cause of ambulatory setting. A total of 335 medical
records were finally included in the study.
Of these 201 (60%) were male. Median age
was 68 years (range 18–97 years). 
Comorbidities and predisposing factors
Some 96.4% of patients were suffering from
comorbidities and factors predisposing to pneu-
monia, 3.6% (12) had no comorbidities. Comor-
bidities and predisposing factors are listed in table
1. The three most important comorbidities with
implications on survival included chronic obstruc-
tive pulmonary disease (COPD) in 24.2% of pa-
tients, carcinoma in 20.9%, and smoking as pre-
disposing factor in 17.6%. Coronary heart disease
and diabetes mellitus with 11% each were quite
common. Immunosupression of any kind was the
least common underlying disease: four male pa-
tients were HIV positive (1.2%), two were renal
transplant recipients (0.6%), two were patients
with chronic lymphatic leukemia (CLL) under
immunosuppressive drug therapy (0.6%), and one
was a heart transplant recipient (0.3%).
Localisation of pneumonia
Pneumonic consolidation documented either
clincally, radiologically or both were most com-
monly found in the inferior lobes (72.8%). The su-
perior lobes were affected in 20% of the patients,
and 21.1% (71 patients) had bilateral pneumonic
infiltrates.
Diagnostic procedures
Specific etiologies were searched for in 87.5%
of patients (293/335) and could be assigned in
33.4% (98/293) of patients (see table 2). A total of
12.5% of patients were diagnosed having pneu-
monia according to clinical and radiologic aspects
without any further diagnostic tests such as blood
cultures, sputum or serology. Blood cultures were
drawn in different numbers in 57.7% (169/293) of
patients; 9.5% of blood cultures grew an organism
(16/169). Sputum cultures were taken in 51.2%
(150/293) of patients and were positive in 46.6%
(70/150). Serology was performed in 6% (17/293)
and was positive in 58.8% (10/17). Pleural effu-
sions were analyzed in 9/293 patients (3%) and
yielded a positive result in two cases (22.2% of all
effusions). 
Bacteriology
The most common etiology found was ordi-
narily encapsulated bacteria: S. pneumoniae in
30.9% of patients (n = 97), Haemophilus in 24.7%
with subspecies H. influenzae 75% and H. para-
influenzae 25% (see table 3). S. pneumoniae was
followed by Klebsiella 12.4% with K. pneumoniae
83%, and K. oxytoca 17%. Pseudomonas accounted
for 12.4% of CAP, thereof 66% P. aeruginosa and
33% others like P. fluorescens and related bacteria
such as Stenotrophomonas maltophilia. 
Non-encapsulated grampositive bacteria were
identified in 9.3% of the patients, including viri-
dans streptococci 44% (of these S. milleri (anginosus)
33% and others 22%) and Staphylococcus aureus
8.6%. No methicillin-resistant S. aureus (MRSA)
was found.
So-called atypical bacteria like Legionella pneu-
mophila (serology =1:256) accounted for 7.5%, and
Chlamydia pneumoniae for 3.1% of all pneumonias
with identified bacterial etiology.
Gramnegative bacteria were rather rare:
Moraxella catharralis in 5.4%, Enterobacter sp. in
4.3%, Citrobacter in 3.1%, of these C. freundii 66%
and C. diversus 33%. Acinetobacter baumanni ac-
counted for 2.1%, Proteus vulgaris for 2.1% and
Morganella morgani for 1% of known etiologies. 
Treatment
An antibiotic treatment was administered to
330 of 335 patients (98.5%), and 1.5% were not
treated because of terminal illness. Monotherapy
was installed in 45.4% (150/330) patients, two or
more antibiotics were given to 54.6% (180/330)
patients.
The three most commonly prescribed antibi-
otics were amoxicillin/clavulanic acid in 77.3%,
clarithromycin in 41% and ceftriaxone in 16.6%.
The antibiotics are completely listed according to
their frequency of prescription in table 4. 
Macrolides other than clarithromycin were
used only rarely (<1%). 
If an aminoglycoside had to be added genta-
micin was preferred over tobramycin (3.6 vs. 0.6%).
Other aminoglycosides were not used. 
The glycopeptid antibiotic vancomycin was
prescribed in 1.8% of patients. There was no me-
thicillin-resistant S. aureus found or treated.
Duration of therapy
Thirty-three out of 330 (10%) treated patients
had to be excluded because of missing data. The
remaining 297 (90%) patients were treated with a
mean duration of 12.1 days (range 1–42).
Outcome
A total of 245/335 (73.1%) patients had a
favourable outcome and were discharged in good
condition. Around 16.7% (56/335) of patients had
a protracted illness with delayed resolution and
either prolonged hospital stay, need for intensive
care, intubation, or several of these complications.
Five out of 335 (<1%) patients could not be cate-
gorized because of unspecific documentation, or
transfer to other hospitals.
Overall mortality due to pneumonia or other
illnesses was 8.6% (29/335 patients). 
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% n
1. Bacterial etiologies 
(listed according to frequency)
S. pneumoniae 30.9 30
Haemophilus spp. 24.7 24
– H. influenzae 18 
– H. parainfluenzae 6
Klebsiella spp. 12.4 12
– K. pneumoniae 10 
– K. oxytoca 2
Pseudomonas spp. 12.4 12 
– P. aeruginosa 8 
– others (Stenotrophomonas m., 4
P. fluorescens u.a.) 
Streptococci 9.3 9 
– S. viridans 4 
– S. milleri (anginosus) 3 
– others 2
S. aureus* 8.2 8
Moraxella catharralis 5.4 5
Enterobacter sp. 4.3 4
Citrobacter spp. 3.1 3
– C. freundii 2 
– C. diversus 1
Acinetobacter baumanni 2.1 2
Proteus vulgaris 2.1 2
Morganella morgani 1 1
2. So-called “atypical bacteria”
Legionella pneumophila** 7.5 7
Chlamydia pneumoniae 3.1 3
* Methicillin-resistant Staphylococci were not found 
** Titer = />1:256
Table 3
Bacteriology (n = 97).
% n
Amoxicillin/Clavulanic acid 77.3 255
Clarithromycin 41.2 136
Ceftriaxone 16.6 55
Gentamicin 3.6 12
TMP/SMX 3 10
Ciprofloxacin 2.1 7
Penicillin 1.8 6
Vancomycin 1.8  6
Amoxycillin 1.8 6
Metronidazol 1.5 5
Clindamycin 1.2  4
Cefuroxim 1.2 4
Cefepime 0.9 3
Ceftazidim 0.6 2
Doxycyclin 0.6 2
Tobramycin  0.6 2
Erythromycin  0.3 1
Azithromycin  0.3  1
* According to frequency of prescription
Table 4
Antibiotic treatment*
(n = 330).
The typical patient hospitalised with pneumo-
nia was elderly (mean 68 years), a male (60%), and
suffered in 96.4% of the cases from comorbidities
such as COPD, carcinoma, cardiovascular disease
or others. These findings are in line with the pop-
ulation based study by Marston et al. [6]: the an-
nual incidence of CAP was highest among the eld-
erly (>65 years) amounting to 993/100,000 inhab-
itants compared to the middle-aged (45–64 years)
with 248/100,000 inhabitants. 
The annual incidence of CAP found by
Marston [6] was significantly higher in men 
than women (291.4/100 000 vs. 244.8/100 000, p
<0.001) with highest rates among elderly males
(56% higher than elderly females). 
The prevalence of at least one comorbid illness
is relatively high in our study population compared
to the study by Meehan et al. (1997; 96.4% vs.
58.2%). This difference seems to be explained by
the fact that Meehan [4] did not include predis-
posing comorbidities like diabetes or immunosup-
pression. Comorbidities such as history of cancer,
which applied to 21% of our patients may lead to
higher mortality. In their study including 18,016
in-hospital patients with pneumonia and history of
cancer, Iezzoni et al. [7] found a significantly raised
mortality of 16.7% with an odds ratio of 2.32 (95%
CI 2.04–2.65, p <0.001), i.e. mortality in these pa-
tients was twice as high compared to the overall
mortality in our study.
A microorganism considered as etiologic was
found in 33.4% of our patients comparable to the
results of Gilbert et al. [8], who found a bacterial
etiology in 29.9% of 1328 in-patients. Including
both bacterial and viral etiologies Almirall et al.
(2000) found in a mixed in- and out-patient setting
(n = 232) an identifiable etiology in 44.8% of pa-
tients. 
In our study serology was taken in 6% of di-
agnosed patients (17/293) and had a high yield
of 58.8% (10/17) positive results; sputum cul-
tures were taken in 57.7% (169/293) of diag-
nosed patients and yielded positive results in
9.5% of patients (16/169). Pleural effusions
yielded a positive result in 22.2% and blood cul-
tures in 9.5%. 
Sputum with Gram’s staining and culture are
generally recommended provided that cytologic
screening confirms the presence of lower-airway
secretions and that the specimens are obtained be-
fore antibiotic treatment [9]. A recent study [10]
showed a high sensitivity and specificity of gram’s
stain for pneumonia caused by S. pneumoniae (57%
and 97%) and H. influenzae (82% and 99%). Good
quality samples of sputum (<10 squamous cells and
>25 leukocytes/low-power field) were obtained in
39% of patients.
The frequency of positive blood cultures is
consistent with a cumulative frequency of 11% in
12 series including 2,935 patients [9]. Meehan et
al. [4] found that blood cultures drawn within the
Discussion
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first 24 hours of hospital admission were associated
with lower than 30-day mortality (OR 0.90, 95%
CI, 0.81–1.00). Positive blood cultures may be
associated with a slightly, but not significantly 
(p = 0.44) higher mortality: Iezzoni et al. [7] found
a mortality rate of 14.4% (OR 1.08, 95% CI
0.88–1.32) in patients with positive blood cultures,
suggesting that a positive blood culture may indi-
cate a more severe or prolonged bacteremia. Blood
cultures are more frequently positive in pneumo-
coccal pneumonia (25%) associated with a poor
prognosis [11].
Drainage of pleural effusions is indicated in
patients with significant effusion, enigmatic pneu-
monia, or failure to respond to therapy [9, 11].
Usually pH, glucose, protein, lactate dehydroge-
nase and white blood cell counts are measured. 
Although serology was positive in almost 60%
of our samples the cost-benefit ratio of serology for
Legionella species, Mycoplasma spp. and Chlamydia
spp. may be low because of missing impact on de-
cision making [6]. Another unsolved problem is the
interpretation and cut-off levels of serology titer
results. Serology is therefore generally not advised.
Urinary antigen detection of Legionella pneumo-
phila serogroup 1 has good sensitivity and speci-
ficity but may require up to five days to become
positive [11].
As expected encapsulated bacteria like S. pneu-
moniae was the most common etiologic agent.
Marston et al. [6] found in their population-based
study of 2,776 patients hospitalised for pneumonia
a rate of 12.6%, Bartlett [9] identified 5 to 18%
(USA) S. pneumoniae compared to 31% in our
study. The higher pneumonia rate probably de-
rives from the fact that Marston included viral as
well as bacterial etiologies. Another possibility is
geographical differences in the incidence of pneu-
mococcal disease. 
H. influenzae ranges as second most common
bacterial etiology with 24.7% of known etiologies
compared to 6.6% in the study of Marston and 3
to 10% in the survey of Bartlett. Almirall et al. [12]
found in their population-based study in Barce-
lona, Spain, only one case of H. influenzae pneu-
monia in 114 causative agents identified. Method-
ological bias or geographical parameters might
cause this difference: Whereas all of our patients
were hospitalised, 38.6% of patients in the study
of Allmirall et al. were not. Therefore incidence of
H. influenzae pneumonia might be more common
in hospitalised patients with CAP and be an indi-
cator of more severe illness.
Klebsiella species accounted for 12.4% of our
patients hospitalised with CAP compared to 1% in
the study of Marston et al. including definite,
probable, and possible bacteriologic diagnosis. 
Geographical variations can make it difficult
to compare the incidence of bacterial etiologies
and antibiotic recommendations for CAP treat-
ment. One vivid example is the prevalence of peni-
cillin-resistant S. pneumoniae, which show highest
rates in South Africa, the Far East, and Southern
Europe. Even within one single country dramatic
variations may be found [13].
The three most commonly used antibiotics
were amoxicillin/clavulanic acid, clarithromycin
and, ceftriaxone. Because of the above-mentioned
geographical variations in bacterial etiologies for
CAP and resistance patterns, evidence-based rec-
ommendations for therapy are scarce. Read [13]
suggests that aminopenicillins, macrolides, fluoro-
quinolones, and some cephalosporins may have
equivalent efficacy in the treatment of mild to
moderate CAP. For the choice of treatment of
severe pneumonia there is little data. In our study,
gentamicin was given as the fourth most used
antibiotic; this is comparable to the multicenter,
prospective study of Gilbert et al. [8] where it was
the third most used antibiotic after cefuroxime and
erythromycin.
The mean duration of antibiotic therapy was
12.1 days in our study. Because of the above-men-
tioned restrictions regarding local distribution and
resistance patterns of microorganisms there exist
no strict recommendations. All the same, treat-
ment duration seems to be comparable in different
countries. In the prospective multicenter cohort
study by Gilbert et al. [8] of 927 out-patients and
1,328 in-patients the median treatment durations
were 12 days for out-patients and 14 days for in-
hospital including upon-discharge treatment.
Marston et al. [6] found in their study of 2,776
in-patients with CAP an overall mortality rate of
8.8% which resembles our results with an overall
mortality of 8.6%. Studies including out-patients
like the survey of Almirall et al. [12] show lower
mortality rates (5%). In-patients with CAP may
show mortality rates of up to 10 to 25% [9]. 
There are several restrictions to this study that
have to be mentioned. First, it is retrospective and
not prospective. Data had to be extracted on the
basis of medical charts, which implied partially in-
complete answers to questions such as how pneu-
monia was exactly diagnosed. Second, diagnosis
was made by attending doctors without structured
diagnostic procedure but on clinical grounds. This
approach reflects local hospital practice. Third,
bacteriological spectra may differ from one geo-
graphical area to another. It therefore may be dif-
ficult to compare study results from different areas
and antibiotic therapy recommmendations.
In conclusion we found the typical patient with
CAP to be elderly and male and suffering from
comorbidities. Drawing blood cultures and spu-
tum Gram’s stain are the most common diagnos-
tic procedures, and are recommended to identify
and treat properly a possible causative microbial
agent after initial empiric antimicrobial therapy.
Encapsulated bacteria are a dominant cause of
pneumonia beeing treated most often with amo-
xicillin/clavulanic acid, clarithromycin, or ceftria-
xone. With an overall mortality of 8.6% in our
survey, pneumonia remains an important cause of
death in patients requiring hospitalisation.
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